Entering text into the input field will update the search result below

Teva launches generic Epzicom in U.S.

  • Teva Pharmaceutical Industries (NYSE:TEVA +0.5%) announces its U.S. commercial launch of a generic equivalent to ViiV Healthcare's Epzicom (abacavir and lamivudine) tablets, 600 mg/300 mg. It is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection.
  • According to IMS, the U.S. market for the branded product is ~$450M.
  • ViiV Healthcare is the HIV-focused company formed by GlaxoSmithKline (GSK +0.9%) and Pfizer (PFE +0.1%).

Recommended For You

About TEVA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TEVA--
Teva Pharmaceutical Industries Limited